by Shahid Ali, MD; Shagufta Jabeen, MD; Rebecca J. Pate, MD; Marwah Shahid, MS; Sandhya Chinala, MD; Milankumar Nathani, MD; and Rida Shah, MD Drs. Ali, Chinala, Nathani, and Shah
by Randy A. Sansone, MD, and Lori A. Sansone, MD R. Sansone is a professor in the Departments of Psychiatry and Internal Medicine at Wright State University School of Medicine
by Muruga A. Loganathan, MD; Manasa Enja, MD; and Steven Lippmann, MD Dr. Loganathan is a resident in the Department of Psychiatry, Allegheny General Hospital, Pittsburgh, Pennsylvania; Dr. Enja is
Dear Editor: Multiple sclerosis (MS) is a relatively frequent inflammatory autoimmune illness of the central nervous system affecting about 2.5 million people around the world and representing the most common
Dear Editor: Atypical long-acting injectable (LAI) antipsychotics may improve treatment options for patients with serious mental illnesses, such as schizophrenia and bipolar disorder.[1] A systematic review of 1,700 outpatients from
The latest in neuroscience—sorted and summarized for you Welcome to the Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to
The latest in neuroscience—sorted and summarized for you Welcome to the Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to
The latest in neuroscience—sorted and summarized for you Welcome to the Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to
The latest in neuroscience—sorted and summarized for you Welcome to the Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to
The latest in neuroscience—sorted and summarized for you Welcome to the Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to
The latest in neuroscience—sorted and summarized for you Welcome to the Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to
Innov Clin Neurosci. 2015;12(5–6 Suppl B):3–19. CNS Drug Compounds/Therapies/Devices Long-acting injectable antipsychotics (LAIs) in outpatient treatment of DMS-IV-R schizophrenia Presenters: Bellnier T, Patil K, Ortega T, Seeger G Affiliations: SUNY
Dear Colleagues: Welcome to the March–April 2015 issue of Innovations in Clinical Neuroscience (ICNS). First, I would like to call to your attention the supplement that accompanies this issue of
by Rajshekhar Bipeta, MBBS, DPM, DNB (psych); Srinivasa SRR Yerramilli, MD (psych); Ashok Reddy Karredla, MD (psych); and Srinath Gopinath, MBBS, DPM Dr. Bipeta is a consultant psychiatrist from Rajasri
by Murali K. Kolikonda, MD; Suneela Cherlopalle, MD; Manasa Enja, MD; and Steven Lippmann, MD Drs. Kolikonda, Cherlopalle, Enja, and Lippmann are with the University of Louisville School of Medicine,
by Mitali Wadekar, MD; Anil Sharma, MD, MBA; and Gina Battaglia, PhD Drs. Wadekar and Sharma are with IRB Company, Inc., Buena Park, California, and Dr. Bittaglia is an independent
by Randy A. Sansone, MD, and Lori A. Sansone, MD R. Sansone is a professor in the Departments of Psychiatry and Internal Medicine at Wright State University School of Medicine
by Ann McNary, JD Ms. McNary is Senior Risk Manager, Professional Risk Management Services, Arlington, Virginia. Innov Clin Neurosci. 2015;12(3–4):37–40.
Innov Clin Neurosci. 2015;12(3–4):11–13.
Innov Clin Neurosci. 2015;12(3–4):10–11.